央视网消息：农业农村部最新数据显示，10月份全国菜篮子指数为133.2，环比下降2.62个点，其中，蔬 菜价格较上月小幅回落。 农业农村部：10月份蔬菜价格较上月小幅回落 10月份，农业农村部监测的28种蔬菜全国平均批发价为每公斤5.9元，环比下降2.5%，同比上涨21.4%。 分品种看，环比价格17种下降，11种上涨，菠菜、油菜、黄瓜价格环比降幅超过10%。 中国农业科学院农业信息研究所副研究员 张晶：10月份全国蔬菜价格小幅回落主要原因是10月份天气 条件有利于田间秋茬蔬菜生长，露地蔬菜大量上市，设施蔬菜供应逐步恢复，各地蔬菜产能有所增加。 专家表示，目前夏秋蔬菜衔接期间价格的高位震荡已经度过，尤其是一些生长周期较长的蔬菜，在10月 中下旬相继完成产地转换，西红柿等部分品种供应偏紧的状况逐步得到缓解，加上耐储的萝卜、甘蓝等 品种量足价稳，拉动菜价整体回落。 张晶：预计后期蔬菜价格将保持季节性下行，前期推迟上市的品种逐步恢复，设施生产的黄瓜、西红 柿、辣椒等陆续上市，后期的蔬菜供应量将进一步增加，秋菜的在途损耗少、保鲜成本降低，菜价将继 续回落。 北京：供应增加 部分蔬菜价格降幅明显 在北京，近期随着产地供 ...

证券研究报告·公司点评报告·医药商业 老百姓（603883） 2024 年三季报点评：利润受新店爬坡及基数 影响短期承压，火炬项目持续提利 2024 年 11 月 01 日 买入（维持） | --- | --- | --- | --- | --- | --- | |------------------------------|--------|--------|---------|--------|----------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 20176 | 22437 | 23459 | 25914 | 28567 | | 同比（ % ） | 28.54 | 11.21 | 4.55 | 10.46 | 10.24 | | 归母净利润（百万元） | 784.96 | 929.02 | 825.10 | 950.84 | 1,085.84 | | 同比（ % ） | 17.29 | 18.35 | (11.19) | 15.24 | 14.20 | | EPS- 最新摊薄（元 ...

公 司 研 究 医 药 生 物 老百姓 沪深300 公 司 简 评 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 | --- | --- | |---------------------------|-------------| | | | | 数据日期 Table_cominfo] | 2024/10/31 | | 收盘价 | 16.07 | | 总股本 ( 万股 ) | 76,023 | | 流通 A 股 /B 股 ( 万股 ) | 75,792/0 | | 资产负债率 (%) | 64.41% | | 市净率 ( 倍 ) | 1.62 | | 净资产收益率 ( 加权 ) | 9.14 | | 12 个月内最高 / 最低价 | 36.90/11.90 | [Table_Reportdate] 2024年11月01日 [Table_invest] 买入（维持） 报告原因：业绩点评 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 w ...

公 司 报 告 公 司 季 报 点 评 证 券 研 究 报 告 2024年11月01日 医药 老百姓(603883.SH) 业绩承压，提升利润率为经营重点 推荐 ( 维持) 平安观点： ■ 股价:16.07元 | --- | --- | |------------------------|--------------------------------| | 行业 | 医药 | | 公司网址 | www.lbxdrugs.com | | 大股东 / 持股 | 老百姓医药集团有限公司 /26.12% | | 实际控制人 | 谢子龙 , 陈秀兰 | | 总股本 ( 百万股 ) | 760 | | 流通 A 股 ( 百万股 ) | 758 | | 流通 B/H 股 ( 百万股 ) | | | 总市值 ( 亿元 ) | 122 | | 流通 A 股市值 ( 亿元 ) | 122 | | 每股净资产 ( 元 ) | 9.16 | | 资产负债率 (%) | 64.4 | | 行情走势图 | | | | | 证券分析师 | --- | |------------------------| | | | 投资咨询资格编号 | ...

f 隔证券 医药生物/医药商业 公 司 研 究 老百姓（603883.SH） 2024 年 10 月 31 日 2024Q3 利润端承压，火炬项目稳步推进提毛利 ——公司信息更新报告 投资评级：买入（维持） | --- | --- | |---------------------------|---------------------------| | | | | 余汝意（分析师） | 巢舒然（联系人） | | yuruyi@kysec.cn | chaoshuran@kysec.cn | | 证书编号： S0790523070002 | 证书编号： S0790123110015 | 2024Q3 利润端承压，毛利率同比提升，维持"买入"评级 2024Q1-Q3 公司实现营收 162.32 亿元（同比+1.19%，下文皆为同比口径）；归母 净利润 6.30 亿元（-12.06%）；扣非归母净利润 6.07 亿元（-5.94%）。Q3 单季度， 公司实现营收 52.92 亿元（+1.18%）；归母净利润 1.27 亿元（-37.32%）；扣非归 母净利润 1.25 亿元（-19.10%）。从盈利能力来看，202 ...

Revenue and Profit Performance - Revenue for the first three quarters of 2024 reached RMB 16,232,148,089, an increase of 1.19% year-over-year[2] - Net profit attributable to shareholders of the listed company for the first three quarters of 2024 was RMB 630,147,823, a decrease of 12.06% year-over-year[2] - Revenue for the first three quarters of 2024 reached 16.232 billion yuan, a year-on-year increase of 1.19%[14] - Net profit attributable to shareholders of the listed company for the first three quarters of 2024 was 630 million yuan, a year-on-year decrease of 12.06%[14] - Total revenue for the first three quarters of 2024 reached RMB 16,232,148,089, a slight increase from RMB 16,041,526,841 in the same period of 2023[36] - Net profit attributable to parent company shareholders reached 630,147,823 yuan, a decrease from 716,560,499 yuan in the same period last year[37] - Total operating revenue for the first three quarters of 2024 was 18,599,452,504 yuan, compared to 18,265,401,747 yuan in the same period of 2023[39] Cash Flow and Financial Position - Net cash flow from operating activities for the first three quarters of 2024 was RMB 1,255,721,494, a decrease of 12.14% year-over-year[3] - Total assets as of the end of the third quarter of 2024 were RMB 21,211,311,937, a slight decrease of 0.09% compared to the end of the previous year[3] - Equity attributable to shareholders of the listed company as of the end of the third quarter of 2024 was RMB 6,961,742,913, an increase of 3.89% compared to the end of the previous year[3] - Net cash flow from operating activities was 1,255,721,494 yuan, down from 1,429,230,229 yuan in the previous year[39] - Total assets as of September 30, 2024, were RMB 21,211,311,937, slightly down from RMB 21,230,999,976 at the end of 2023[34] - Total liabilities as of September 30, 2024, were RMB 13,663,251,217, a decrease from RMB 13,941,960,115 at the end of 2023[35] - Shareholders' equity increased to RMB 7,548,060,720 as of September 30, 2024, up from RMB 7,289,039,861 at the end of 2023[35] - Cash and cash equivalents stood at RMB 2,099,006,221 as of September 30, 2024, up from RMB 1,974,984,513 at the end of 2023[32] - Inventory decreased to RMB 3,741,313,824 as of September 30, 2024, from RMB 4,152,484,967 at the end of 2023[32] - Long-term equity investments increased to RMB 85,220,294 as of September 30, 2024, up from RMB 67,821,191 at the end of 2023[34] - Cash and cash equivalents at the end of the period were 950,194,621 yuan, down from 1,028,321,991 yuan at the end of the previous year[41] - Total cash inflow from financing activities was 2,026,845,742 yuan, up from 1,100,273,193 yuan in the previous year[40] - Total cash outflow from investment activities was 464,461,047 yuan, compared to 706,820,762 yuan in the same period last year[40] - Net cash flow from investment activities was -439,382,336 yuan, compared to -343,615,820 yuan in the previous year[40] Store Operations and Expansion - The company had 15,591 stores as of September 30, 2024, including 10,300 directly operated stores and 5,291 franchised stores[19] - In the first three quarters of 2024, the company added 2,368 new stores, including 1,264 directly operated stores and 1,104 franchised stores[19] - The company closed 351 stores in the first three quarters of 2024, including 144 directly operated stores and 207 franchised stores[19] - Total number of stores reached 15,591, including 10,300 directly operated stores and 5,291 franchised stores[24] - In Q3 2024, the company added 2,368 new stores, with 1,264 directly operated stores and 1,104 franchised stores[24] - The company completed 3 acquisition projects in the reporting period, totaling 41 stores with a combined amount of 40.46 million yuan[22] - The company's stores in prefecture-level cities and below accounted for 77% of the total, with 80% of new stores in 2024 located in these areas[24] - The average preparation cycle for new directly operated stores in Q3 2024 was 40 days, a reduction of 5 days compared to the same period last year[24] Gross Profit and Margin - Gross profit margin for the first three quarters of 2024 was 33.87%, an increase of 1.36 percentage points year-on-year[14] - Revenue from retail business in the first three quarters of 2024 was 13.314 billion yuan, with a gross profit margin of 38.03%[15] - Revenue from the Chinese medicine business in the first three quarters of 2024 was 1.204 billion yuan, with a gross profit margin of 45.08%[17] - Revenue from non-drug products in the first three quarters of 2024 was 2.057 billion yuan, with a gross profit margin of 39.53%[17] - The gross profit margin for the first three quarters of 2024 was 33.87%, an increase of 1.36 percentage points year-on-year[25] - The company's promotional gross profit ROI was 1.49 in Q3 2024, a year-on-year increase of 6.1%[28] Online and Digital Performance - The company's online channel sales (including franchise) reached approximately 1.74 billion yuan in the first three quarters of 2024, a year-on-year increase of 16%[27] - The company's O2O and B2C sales rankings were fifth and third in the market, respectively, in Q3 2024[27] - The private domain mini-program sales increased by 22.6% year-on-year in Q3 2024, with DAU increasing by 118%[27] - The company has 12,555 O2O delivery service stores and 728 24-hour stores as of the end of the reporting period[27] - The total number of company members reached 97.17 million, with 14.65 million active members in Q3 2024 and over 3.1 million new registered members[27] Shareholder and Equity Information - The company's top shareholder, Laobaixing Pharmaceutical Group Co., Ltd., holds 26.12% of the shares, with 123,204,000 shares pledged[10] - Equity attributable to shareholders of the listed company as of the end of the third quarter of 2024 was RMB 6,961,742,913, an increase of 3.89% compared to the end of the previous year[3] - Shareholders' equity increased to RMB 7,548,060,720 as of September 30, 2024, up from RMB 7,289,039,861 at the end of 2023[35] Earnings and Return on Equity - Basic earnings per share for the third quarter of 2024 were RMB 0.17, a decrease of 37.31% year-over-year, primarily due to the decline in net profit attributable to shareholders[9] - The company's weighted average return on equity (ROE) for the first three quarters of 2024 was 9.14%, a decrease of 1.58 percentage points year-over-year[3] - Basic earnings per share (EPS) for the quarter were 0.83 yuan, compared to 0.94 yuan in the same period last year[38] - Total comprehensive income for the period was 743,726,347 yuan, a decrease from 820,172,473 yuan in the previous year[38] Non-Recurring Items and Impairment - Non-recurring gains and losses for the first three quarters of 2024 amounted to RMB 23,069,846, including government subsidies and gains from financial assets[6] - Total assets impairment loss was -10,447,829 yuan, compared to -2,659,467 yuan in the same period last year[37] Chronic Disease Management and Brand Exposure - The company's chronic disease management services have accumulated over 16.84 million records, 90.5 million self-tests, and 37.36 million follow-ups as of the end of the reporting period[30] - The company's brand exposure exceeded 1.4 billion times annually, with over 77.97 million views of brand videos on the self-media matrix in Q3 2024[31] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were RMB 15,333,787,742, compared to RMB 15,075,343,081 in the same period of 2023[36] - Sales expenses increased to RMB 3,577,910,985 in the first three quarters of 2024, up from RMB 3,355,680,232 in the same period of 2023[36] - Management expenses rose to RMB 825,589,932 in the first three quarters of 2024, compared to RMB 703,469,470 in the same period of 2023[36] Inventory and Turnover - The inventory turnover days in Q3 2024 were 98 days, a decrease of 5 days year-on-year[25] - Inventory decreased to RMB 3,741,313,824 as of September 30, 2024, from RMB 4,152,484,967 at the end of 2023[32] Franchise and Alliance Business - The company's franchised business achieved a distribution sales volume of 1.639 billion yuan, a year-on-year increase of 7.5%[24] - The alliance business achieved a distribution sales volume of 280 million yuan, a year-on-year increase of 90.8%[24] Self-Owned Brand and Sales - The company's self-owned brand sales in directly operated stores reached 2.53 billion yuan, accounting for 21.9% of total sales, an increase of 2.4 percentage points year-on-year[25] Outpatient and Internet Prescription Services - The company has 5,347 stores (including 4,170 directly operated and 1,177 franchise) with outpatient coordination qualifications, accounting for 40.49% of directly operated stores[26] - The company has 4,191 stores (including 3,384 directly operated and 807 franchise) that can use internet prescriptions, accounting for 32.85% of directly operated stores[26]

大家好我是老百姓大药房董事会秘书冯世明欢迎大家参加老百姓投资者交流会今天和我们共同参加会议的还有公司总裁王林女士独立董事伍连峰先生独立董事谢子期先生独立董事任明川先生财务总监陈立山先生我们今天的会议会分两个部分 首先我将通过PPT的方式为大家展示公司和行业的最近的经营情况稍后大家如果有感兴趣的问题可以在互动区和我们沟通交流首先我们通过一些简单的数字来为大家描述一下公司目前的发展情况通过20余年的发展老百姓已经成为中国医药零售行业龙头的企业之一 今年的6月30日我们实现了总资产210.3亿元今年上半年实现销售额109.4亿元经营着2.67万个品规目前我们拥有着门店总数14969个覆盖到18个省150个地级市公司拥有会员数量9400万 以及我们的员工包含家门店的员工突破了5万人自2015年在上海证券交易所上市以来公司实现了快速的增长2015年发展至今我们的复合增长门店的复合增长率达到31.89%营业收入去年达到224亿元 收入的年复合增长率达到22.01%去年我们实现了9.29亿元的规模净利润规模利润的复合增长率达到18.4%总体来看我们的综合毛利率始终保持着平稳今年上半年实现了34.32%的综合毛利率 尤为值得 ...

证券代码：603883 证券简称：老百姓 公告编号：2024-064 老百姓大药房连锁股份有限公司 关于参加湖南辖区 2024 年度投资者 网上集体接待日活动的公告 | --- | |----------------------------------------------------------| | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假 | | 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 | | 和完整性承担法律责任。 | 为进一步加强与投资者的互动交流，老百姓大药房连锁股份有限公司（以下 简称"公司"）将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有 限公司联合举办的"湖南辖区 2024 年度投资者网上集体接待日"活动，现将相 关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2024 年 10 月 10 日（星期四） 14:00-17:00。 届时公司高管将在线就公司 2023 年至 2024 半年度 ...

公 司 研 究 医 药 生 物 老百姓 沪深300 [Table_Reportdate] 2024年09月04日 [Table_invest] 买入（维持） 报告原因：业绩点评 举措提升盈利能力 [老百姓（ Table_NewTitle] 603883）：收入端保持稳健，多 ——公司简评报告 公 司 简 评 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 伍可心 S0630522120001 wkx@longone.com.cn | --- | --- | |-----------------------------|-------------| | | | | [ 数据日期 Table_cominfo] | 2024/09/03 | | 收盘价 | 13.46 | | 总股本 ( 万股 ) | 76,023 | | 流通 A 股 /B 股 ( 万股 ) | 75,792/0 | | 资产负债率 (%) | 64.36% | | 市净率 ( 倍 ) | 1.37 | | 净资产收益率 ( 加权 ) | 7.22 | | 12 ...

F原证券 医药生物/医药商业 公 司 研 究 老百姓（603883.SH） 2024 年 09 月 04 日 2024H1 利润端短期承压，毛利率稳中有进 ——公司信息更新报告 投资评级：买入（维持） 余汝意（分析师） yuruyi@kysec.cn 证书编号：S0790523070002 | --- | --- | |-------------------------|-------------| | 日期 | 2024/9/3 | | 当前股价 ( 元 ) | 13.46 | | 一年最高最低 ( 元 ) | 36.90/11.90 | | 总市值 ( 亿元 ) | 102.33 | | 流通市值 ( 亿元 ) | 102.02 | | 总股本 ( 亿股 ) | 7.60 | | 流通股本 ( 亿股 ) | 7.58 | | 近 3 个月换手率 (%) | 142.69 | 股价走势图 -48% -24% 0% 24% 48% 72% 2023-09 2024-01 2024-05 老百姓 沪深300 数据来源：聚源 相关研究报告 《业绩稳健增长，持续加深优势区域 布 局 — 公司信息更新报告》 -202 ...